Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Purchases $24,903.87 in Stock

VolitionRx Limited (NYSE:VNRX) insider Jacob Vincent Micallef acquired 43,691 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $24,903.87. Following the completion of the purchase, the insider now owns 394,352 shares in the company, valued at approximately $224,780.64. This represents a 12.46 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

VolitionRx Stock Down 6.3 %

NYSE VNRX opened at $0.61 on Friday. The company has a 50-day simple moving average of $0.69 and a 200-day simple moving average of $0.67. VolitionRx Limited has a one year low of $0.43 and a one year high of $1.23.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC lifted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 730,448 shares of the company’s stock after acquiring an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

Wall Street Analysts Forecast Growth

VNRX has been the subject of a number of analyst reports. Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com began coverage on shares of VolitionRx in a research report on Friday, December 6th. They issued a “sell” rating for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a report on Tuesday.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.